Related Experiment Video
Updated: Aug 9, 2026
The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Genomics of renal cell cancer-- does it provide breakthrough?
11st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, H-1085, Hungary. kopper@korb1.sote.hu
Abstract:
It is a strong hope that the more we characterize the pathways in an individual tumor, the better we will be able to evaluate the response to a specific therapy. Different array technologies could be powerful tools to achieve this goal, i.e. selecting patients on the basis of the genomic and/or proteomic profiles who would really benefit from the target-designed therapy. Genomic analysis of RCC accumulated ample of data which now can be exploited in clinical management of a previously almost uncontrollable disease. Beside the previously identified genetic abnormalities (VHL, MET, EGFR), CAIX seems to be a novel molecular marker of RCC. Array studies also outlined a small set of tumor markers, vimentin, galectin-3, CD74 and parvalbumin, which can define the individual histologic subtypes of RCC. We are at the beginning to take advantage of the genomic results. Some new approaches will interfere with the progression of RCC (anti-VEGF, anti-VEGFR or anti-EGFR therapies). Further novel molecular targets are available, such as HIF, HSP90 or the IFN-regulated genes, which can be used to the fine-tuning of RCC therapy.
Insights
Characterizing tumor pathways aids therapy response evaluation. Genomic and proteomic profiling, including novel markers like CAIX, can personalize renal cell carcinoma (RCC) treatment and identify new therapeutic targets.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Personalized medicine aims to tailor cancer therapies based on individual tumor characteristics.
- Renal cell carcinoma (RCC) treatment has historically been challenging, necessitating advanced diagnostic and therapeutic strategies.
- Genomic and proteomic analysis offers potential for improved patient selection and treatment efficacy.
Purpose of the Study:
- To explore the utility of array technologies for characterizing tumor pathways in renal cell carcinoma (RCC).
- To identify novel molecular markers for RCC diagnosis and subtyping.
- To discuss emerging therapeutic strategies targeting identified molecular pathways in RCC.
Main Methods:
- Genomic and proteomic analysis using various array technologies.
- Identification and validation of molecular markers associated with RCC.
- Review of current and potential targeted therapies for RCC.
Main Results:
- Genomic analysis of RCC has yielded significant data for clinical management.
- Novel molecular markers such as CAIX, vimentin, galectin-3, CD74, and parvalbumin have been identified in RCC.
- Established genetic abnormalities (VHL, MET, EGFR) and new targets (HIF, HSP90, IFN-regulated genes) are crucial for therapy.
Conclusions:
- Characterizing individual tumor pathways through genomic and proteomic profiling is key to optimizing therapy response.
- Novel markers like CAIX and specific protein sets can aid in RCC subtyping and patient selection.
- Emerging targeted therapies (anti-VEGF, anti-VEGFR, anti-EGFR) and novel molecular targets offer promising avenues for fine-tuning RCC treatment.
More Related Videos
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Related Concept Videos
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:29Pharmacogenomics: Identification of New Drug Targets
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...